Tesis Dra. Aranzazu González Canga:
1. Intravenous pharmacokinetics of ivermectin in sheep and goats. González A, García
JJ, Sierra M, Fernández N, Castro LJ, Sahagún A. Meth Find Exp Clin Pharmacol 2004:26;127.
2. Subcutaneous bioavailability of a new commercial formulation of ivermectin in
goats. González A, García JJ, Diez MJ, Castro LJ, Sierra M, Sahagún A. Meth Find Exp Clin Pharmacol 2005;27:178.
3. Subcutaneous bioavailability of ivermectin in sheep. González A, Sahagún A, Sierra
M, Díez MJ, Fernández N, García JJ. Meth Find Exp Clin Pharmacol 2006;28:156.
4. Pharmacokinetics of a novel formulation of ivermectin after administration to goats.
González A, Sahagún AM, Diez MJ, Fernández N, Sierra M, García JJ. Am J Vet Res 2006;67:323-28.
5. Bioavailability of a commercial formulation of ivermectin after subcutaneous
administration to sheep. González A, Sahagún A, Diez MJ, Fernández N, Sierra M, García JJ. Am J Vet Res 2007;68:101-5.
6. González A, Sahagún AM, Diez MJ, Fernández N, Sierra M, García JJ. The
pharmacokinetic and interactions of ivermectin in humans- A mini review. AAPSJ 2008;10:42-6.
7. González A, Sahagún AM, Diez MJ, Fernández N, Sierra M, García JJ. The
pharmacokinetics and metabolism of ivermectin in domestic animal species. Vet J 2009;179:25-37.
8. González-Canga A, Fernández-Martínez N, Sahagún-Prieto A, Diez-Liébana MJ,
Sierra-Vega M, García-Vieitez JJ. A review of the pharmacological interactions of ivermectin in several animal species. Curr Drug Metabolism2009;10:359-68.
Tesis Dr. Luis J. Castro Robles:
1. Disposition of doxycycline in sheep after intravenous administration. Castro LJ,
García JJ, Diez MJ, Sahagún A, González A, Sierra M. Meth Find Exp Clin Pharmacol 2004;26;149.
2. Intramuscular pharmacokinetics of doxycycline in sheep. García JJ, Castro LJ,
Fernández MN, González A, Diez MJ, Sierra M. Meth Find Exp Clin Pharmacol 2005;27:175.
3. Oral bioavailability of doxycycline in sheep. Sierra M, Castro LJ, Díez MJ, Sahagún
A, Fernández MN, García JJ. Meth Find Exp Clin Pharmacol 2006;28:157.
4. Castro LJ, Sahagún AM, Diez MJ, Fernández N, Sierra M, Garcia JJ.
Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. Vet J 2009;180:389-95.
Tesis Dr. Demetrio Carriedo Ule:
1. Hidrosoluble fiber (Plantago ovata husk) and levodopa I: Experimental study of the
pharmacokinetic interaction. García JJ, Fernández N, Carriedo D, Diez MJ, Sahagún A, González A, Calle A, Sierra M. Eur. Neuropsycholpharmacol.2005;15:497-503.
2. Hidrosoluble fiber (Plantago ovata husk) and levodopa II: Experimental study of
the pharmacokinetic interaction in the presence of carbidopa. Fernández N, Carriedo D, Sierra M, Diez MJ, Sahagún A, Calle A, González A, García JJ. Eur. Neuropsycholpharmacol. 2005;15:505-9.
Tesis Dra. Ángela P. Calle Pardo:
1. Calle AP, García JJ, González A, Anguera A, Molinero C, Sierra M. Levodopa
pharmacokinetic changes induced by Plantago ovata husk when gastrointestinal peristaltism is slowed. Meth Find Exp Clin Pharmacol 2007;29:100.
2. García JJ, Fernández N, Calle AP, Diez MJ, Sahagún A, Sierra M.Effects of
Plantago ovata husk on levodopa (with carbidopa) bioavailability in rabbits with autonomic gastrointestinal disorders. Drug Metab Dispos 2009:37;1434-42.
Tesis Dr. Carlos Prieto Santos:
1. Fernandez N, Prieto C, Sierra M, Diez MJ, Sahagun A, Gonzalez A, Garcia JJ.
Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits. Meth Find Exp Clin Pharmacol 2008;30:1-7.
2. Diez MJ, Garcia JJ, Prieto C, Fernandez N, Sahagun A, Sierra M. The hydrosoluble
fiber/Plantago ovata/ husk improves levodopa (with carbidopa) bioavailability after repeated administration. J Neurol Sci 2008;271:15-20.
Tesis Dra. Rosario Díaz González:
1. Balaña-Fouce R, Redondo CM, Pérez-Pertejo Y, Díaz-González R, Reguera RM.
Targeting atypical trypanosomatid DNA topoisomerase I. Drug Discov Today. 2006;11:733-40.
2. Díaz-González R, Pérez-Pertejo Y, Ordóñez D, Balaña-Fouce R, Reguera RM.
Deletion study of DNA topoisomerase IB from Leishmania donovani: searching for a minimal functional heterodimer. PLoS ONE 2007;2:e1177-e1177.
3. Reguera RM, Pérez-Pertejo Y, Redondo CM, Díaz-González R, Balaña-Fouce R.
Type I DNA topoisomerase from protozoan pathogens as a potential target for anti-tumoral drugs. Medicina (B Aires) 2007;67:747-57.
4. Díaz González R, Pérez Pertejo Y, Redondo CM, Pommier Y, Balaña-Fouce R,
Reguera RM. Structural insights on the small subunit of DNA topoisomerase I from the unicellular parasite Leishmania donovani. Biochimie. 2007;89:1517-27.
5. Reguera RM, Díaz-González R, Pérez-Pertejo Y, Balaña-Fouce R. (2008)
Characterizing the bi-subunit type IB DNA topoisomerase of Leishmania parasites; a novel scenario for drug intervention in trypanosomatids. Curr Drug Targets 2008;9:966-78.
6. Diaz-González R, Pérez-Pertejo Y, Pommier Y, Balaña-Fouce R, Reguera RM.
Mutational study of the "catalytic tetrad" of DNA topoisomerase IB from the hemoflagellate Leishmania donovani: Role of Asp-353 and Asn-221 in camptothecin resistance. Biochem Pharmacol 2008;76:608-19.
7. Díaz-González R, Pérez-Pertejo Y, Prada CF, Fernández-Rubio C, Balaña-Fouce R,
Reguera RM. Novel findings on trypanosomatid chemotherapy using DNA topoisomerase inhibitors. Mini Rev Med Chem 2009;9:674-86.
Tesis Dr. Francisco José Domingo Hernández:
1. Fernández N, Domingo F, Susperregui J, Sierra M, González A, García JJ. Use and
cost of anxiolytics in Spain. Meth Find Exp Clin Pharmacol 2008;30:139.
2. González A, Domingo F, Susperregui J, Diez MJ, Sahagún A, García JJ.
Antidepresant drug consumption in Spain (1997-2004). Meth Find Exp Clin Pharmacol 2008;30:140.
3. Sierra M, Domingo FJ, Susperregui J, Fernández N, Sahagún A, García JJ.
Consumption and economic impact of antiparkinsonian agents in Spain (1997-2004). Meth Find Exp Clin Pharmacol 2009;31:83.
4. García JJ, Domingo FJ, Susperregui J, Diez MJ, Fernández, Sahagún A, Sierra.
Trends of antiepileptic use in Spain. Meth Find Exp Clin Pharmacol 2009;31:83.
Tesis Dr. Hugo Orlando Portilla Portilla:
1. Sierra M, Vaquera J, Portilla HO, Fernández N, Diez MJ, García JJ. Plantago ovata
husk decreases intestinal injury induced by aspirin in rabbits after chronic administration. Meth Find Exp Clin Pharmacol 2007;29:94.
2. Portilla Portilla H, Vaquera Orte J, Sahagún Prieto A, García Vieitez JJ, Diez
Liébana MJ, Fernández Martínez N, Sierra Vega M. Protection conferred by Ispaghula husk against enterocyte impairment induced by aspirin. Eur J Clin Pharmacol 2010;66:101.
Tesis Dr. Luis Hernández Echabarría:
1. García JJ, Sierra M, Fernández N, Molinero C, Anguera A, Hernández L. Plantago ovata husk administration to well controlled Parkinson’s patients improves levodopa pharmacokinetics. Meth Find Exp Clin Pharmacol 2007;29:95.
Tesis Dra. Díez Láiz:
1. Fernández N, Diez R, Molina R, Sahagún A, González A, Vázquez R, Anguera A,
Sierra M. Oral bioavailability of metformin in diabetic rabbits. Effects of fiber supplementation. Meth Find Exp Clin Pharmacol 2009;31:126.
2. Díez Láiz R, Fernández Martínez N, García Vieitez JJ, Diez Liébana MJ, Sahagún
Prieto A, Anguera Vilá A, Sierra Vega M.Glucose and insulin levels after the oral administration of metformin and metformin with Plantago ovata husk to diabetic rabbits. Eur J Clin Pharmacol 2010;66:100.
2 Wissenschaft– Parodontologie Effizienz der Photodynamischen Therapie mit dem Helbo-Verfahren Erste Ergebnisse einer klinisch kontrollierten Studie bei parodontaler Entzündung B. W. Sigusch, A. Völpel, M. Engelbrecht, W. Pfister, E. Glockmann, Jena Die klassischen mechanischen Methoden der Therapie bzw. der adjuvante Ein- Die Anwendung von antiseptischen oder anti- satz von Ant
REGU®-SLIM Es un complejo patentado de efecto multiactivo, remodelador corporal y adelgazante, que acelera los mecanismos naturales de disminución de la grasa subcutánea, a la vez que suaviza y da firmeza a la piel. DESCRIPCION REGU®-SLIM es un granulado amarillento que contiene sustancias naturales como ácido cisteico, cafeína y guaraná, que desencadenan la lipolisis en